PRLD Stock — Prelude Therapeutics Incorporated: Cash, EV, Pipeline

What they do

We believe our approach could result in better targeted cancer therapies. Our discovery excellence has been supported by our steady progress in advancing a pipeline of novel precision oncology development candidates, alone and with partners. We are working with our partner AbCellera Biologics, Inc. ("AbCellera") on an early-stage discovery program involving potent degraders as payloads for novel antibodies targeting tumor specific antigens.

Source: 10-K FY2025 via SEC EDGAR

Share price

$3.60

Market cap

$287.3M

Cash

$151.8M

Enterprise value

$135.5M

Balance sheet

Cash	$151.8M
Debt	$0.0M
Net cash	$151.8M
Enterprise value	$135.5M
Basic shares	79.8M shares
Fully diluted shares	121.6M shares
Fully diluted market cap	$437.8M
Cash per share	$1.90
Quarterly burn	$15.6M
Cash runway	9.7 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

79.8M

Pre-funded warrants

23.2M

Options

18.2M

RSUs

0.4M

Warrants

—

Converts

—

Conv preferred

—

ESPP reserve

—

FDSO

121.6M

Cap table as of 2026-08-06.

Price history

Loading PRLD daily closes…

Loading price history…

Next catalyst

PRT12396 · May 13 - Jun 24 in 18 mo · Phase 1 · Polycythemia Vera (PV); Myelofibrosis (MF); Myeloproliferative Neoplasms (MPNs)

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
May 13 - Jun 24 in 18 mo	PRT12396	Phase 1	Polycythemia Vera (PV); Myelofibrosis (MF); Myeloproliferative Neoplasms (MPNs)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

PRT12396

Phase 1 · Active Modality: small molecule inhibitor

Target JAK2 (V617F)

Indications

polycythemia vera (PV) (Phase 1)
myelofibrosis (MF) (Phase 1)

Catalysts

— H2 2026

Status note Lead candidate; mutant-selective JAK2V617F inhibitor. IND cleared Feb 2026; enrolling open-label multicenter Phase 1 safety/efficacy study in PV and MF patients.

PRT13722

Preclinical · Active

Target KAT6A

Indications

HR+ breast cancer (Stage not disclosed)

Catalysts

— Q4 2026
— mid-2026

Status note Lead development candidate; preclinical data presented at AACR 2026. Pending IND clearance, Phase 1 in HR+ breast cancer expected to initiate Q4 2026. Modality/target not stated in excerpts.

SMARCA2/4 dual degrader programs

Preclinical · Active Modality: degrader (ADC-conjugated payload)

Target SMARCA2/4

Status note Described as a novel, potent SMARCA2/4 dual degrader as a degrader payload conjugated to multiple antibodies; preclinical PoC disclosed Oct 2024. Filing states the company has paused or discontinued these programs (expense reclassification); filing does not specify which.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	PRT12396
Lead indication	Polycythemia Vera (PV)
Lead phase	Phase 1
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07469891	Phase 1	Recruiting	Sponsor	PRLD	—	Polycythemia Vera (PV); Myelofibrosis (MF); Myeloproliferative Neoplasms (MPNs)	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Prelude Therapeutics Incorporated on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	19,404,757	+2,284,602	1.96%	2026-08-14
Baker Bros. Advisors	10,123,824	no change	0.27%	2026-08-14
RA Capital Management	6,475,882	+6,475,882	0.30%	2026-08-14
Sphera Biotech	1,019,832	+461,493	0.78%	2026-08-14
ADAR1 Capital Management	900,900	+748,075	0.23%	2026-08-14
EcoR1 Capital	0	-947,049	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

PRLD — Prelude Therapeutics Incorporated ☆